Twelve pharmaceutical leaders and chief scientists present efficacy data and status reports on their vaccines against SARS-CoV-2; Anthony Facui and Moncef Slaoui deliver keynotes

Media and Event Registration for February 2 and February 3, 2021, Symposium

New York, NY – A remarkable number of pharmaceutical company leaders and chief scientists will come together at a two-day symposium to present efficacy data and updates on twelve vaccines and vaccine candidates. This includes the Moderna and Pfizer mRNA vaccines that have been approved in the US for emergency use. Other topics will include: the clinical epidemiology of COVID-19; the virology, immunology, and genetics of SARS-CoV-2; and research on COVID-19 vaccines in in the elderly. 

For a complete agenda and a listing by day/time, see: nyas.org/covidvaccine21

For Media Registration, contact: Roger Torda / [email protected] / 914 262 8700.

 

Keynotes:

• Moncef Slaoui, Biden administration consultant and former chief scientific advisor to Operation Warp Speed  (10:15 AM EST Tues Feb 2)
• Anthony Fauci, director of the National Institute of Allergy and Infections Diseases, NIH.   “The Year in Review: A Vaccinologist’s Perspective” (11 AM EST Tues Feb 2)

Efficacy Data Updates on the Messenger RNA Vaccines Approved in the US for Emergency Use:

• Tal Zaks, Chief Medical Officer of Moderna (2:50 PM EST Tues Feb 2)
• Kathrin Jansen, senior VP and Head of Vaccine Research and Development at Pfizer (2:50 PM EST Tues Feb 2)

Efficacy Data Updates on Candidate Vaccines Now in Phase 3 Trials:

• Gregory M. Glenn, Novavax (4 PM EST, Tues Feb 2)
• Sarah Gilbert, University of Oxford/AstraZeneca (10:35 AM EST Wed Feb 3)
• Xuefeng Yu, CanSino Biologics (11:05 AM EST Wed Feb 3)
• Hanneke Schuitemaker, Janssen/Johnson & Johnson (11:45 AM EST Wed Feb 3)

Status Updates on Vaccines in Phase 1 and Phase 2 Trials:   

• J. Robert Coleman, Codagenix (4:30 PM EST Tues Feb 2)
• J. Joseph Kim, Inovio (4:50 PM EST Tues Feb 2)
• Thomas Lingelbach, Valneva (12:15 PM EST Wed Feb 3)
• Stefan O. Mueller, CureVac (12:35 PM EST Wed Feb 3)
• Sean Tucker, Vaxart (1:05 PM EST Wed Feb 3)
• J. Joseph Kim, Inovio (4:50 PM EST Tues Feb 2)

Additional Research Sessions and Topics

Epidemiology of COVID-19, Noon EST Tues Feb 2

• “Tracking Changes in SARS-CoV-2 Spike,” Bette Korber, Los Alamos National Laboratory. 

 Virology, Immunology & Genetics of SARS-CoV-2, 12:35 PM EST Tues Feb 2

• “Virology of SARS-CoV-2,” Ralph Baric of the University of North Carolina School of Medicine
• “Immunology of SARS-CoV-2,” Shane Crotty, La Jolla Institute for Immunology
• “Longitudinal Immune Profiling of Moderate and Severe COVID-19,” Bali Pulendran, Stanford University.

 Modern Vaccinology in Responding to New Epidemics, 5:10 PM EST Tues Feb 2

• Presentation by John R. Mascola, National Institute of Allergy and Infectious Diseases.

 COVID-19 Vaccines for the Elderly, 2:15 PM EST Wed Feb 3

• “Immunosenescence and COVID-19 Vaccines for the Elderly,” Nir Barzalai, Albert Einstein College of Medicine.

 Outbreak Predictions, 2:45 PM EST Wed Feb 3       

• “How to Make Predictions about Future Infectious Disease Risks,” Mark Woolhouse, University of Edinburgh
• “Challenges to Prediction and Prevention of the Next Pandemic Zoonosis,” Kevin Olival, EcoHealth Alliance.

Future Challenges, 3:45 PM EST Wed Feb 3

• “Progress in Novel Treatments for COVID-19 and Beyond,” Annaliesa Anderson, Pfizer
• “Lessons Learned from COVID-19 Vaccine Development for Future Pandemic Preparedness,” Melanie Saville, CEPI
• “Access, Development, and Global Distribution Challenges for COVID-19 Vaccines,” speaker, tbd.
• “The Plague Year of 2020 and Its Effect on Vaccinology,” Stanley Plotkin, University of Pennsylvania.

Scientific Organizing Committee:

• Annaliesa Anderson, PhD (Pfizer)
• Emmanuel Hanon, PhD (GlaxoSmithKline)
• Gregory Glenn, MD (Novavax Inc.)
• Wayne Koff, PhD (Human Vaccines Project)
• Stanley Plotkin, MD (University of Pennsylvania)
• Melanie Brickman Borchard, PhD, MSc (New York Academy of Sciences)

For a complete agenda and a listing by day/time, see: nyas.org/covidvaccine21

This symposium is sponsored by GSK, Novavax, Pfizer, and Latham BioPharm Group.

Complimentary Media Registration

The Academy is pleased to offer journalists complimentary access to this event. Advance registration is necessary. For registration or to facilitate interviews, please contact:  Roger Torda / [email protected] / 914 262 8700 (m)

ABOUT THE NEW YORK ACADEMY OF SCIENCES

The New York of Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science for the benefit of society. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online at  www.nyas.org.